Role of estrogen receptor coregulators in endocrine resistant breast cancer

por Altwegg, Kristin A., Vadlamudi, Ratna K.
Publicado 2021

Global Genomic and Proteomic Analysis Identified Critical Pathways Modulated by Proto-Oncogene PELP1 in TNBC

por Liu, Zexuan, Altwegg, Kristin A., Liu, Junhao, Weintraub, Susan T., Chen, Yidong, Lai, Zhao, Sareddy, Gangadhara R., Viswanadhapalli, Suryavathi, Vadlamudi, Ratna K.
Publicado 2022

Interaction of transcription factor AP‐2 gamma with proto‐oncogene PELP1 promotes tumorigenesis by enhancing RET signaling

por Liu, Junhao, Liu, Zexuan, Li, Mengxing, Tang, Weiwei, Pratap, Uday P., Luo, Yiliao, Altwegg, Kristin A., Li, Xiaonan, Zou, Yi, Zhu, Hong, Sareddy, Gangadhara R., Viswanadhapalli, Suryavathi, Vadlamudi, Ratna K.
Publicado 2021

Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34

por Altwegg, Kristin A., Pratap, Uday P., Liu, Zexuan, Liu, Junhao, Sanchez, John R., Yang, Xue, Ebrahimi, Behnam, Panneerdoss, Durga Meenakshi, Li, Xiaonan, Sareddy, Gangadhara R., Viswanadhapalli, Suryavathi, Rao, Manjeet K., Vadlamudi, Ratna K.
Publicado 2023

Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma

por Pratap, Uday P, Sareddy, Gangadhara R, Liu, Zexuan, Venkata, Prabhakar Pitta, Liu, Junhao, Tang, Weiwei, Altwegg, Kristin A, Ebrahimi, Behnam, Li, Xiaonan, Tekmal, Rajeshwar R, Viswanadhapalli, Suryavathi, McHardy, Stanton, Brenner, Andrew J, Vadlamudi, Ratna K
Publicado 2021

SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance

por Liu, Zexuan, Liu, Junhao, Ebrahimi, Behnam, Pratap, Uday P., He, Yi, Altwegg, Kristin A., Tang, Weiwei, Li, Xiaonan, Lai, Zhao, Chen, Yidong, Shen, Liangfang, Sareddy, Gangadhara R., Viswanadhapalli, Suryavathi, Tekmal, Rajeshwar R., Rao, Manjeet K., Vadlamudi, Ratna K.
Publicado 2022

Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth

por Blankenship, Logan, Pratap, Uday P., Yang, Xue, Liu, Zexuan, Altwegg, Kristin A., Santhamma, Bindu, Ramasamy, Kumaraguruparan, Konda, Swapna, Chen, Yidong, Lai, Zhao, Zheng, Siyuan, Sareddy, Gangadhara R., Valente, Philip T., Kost, Edward R., Nair, Hareesh B., Tekmal, Rajeshwar R., Vadlamudi, Ratna K., Viswanadhapalli, Suryavathi
Publicado 2022

LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer

por Tang, Weiwei, Ramasamy, Kumaraguruparan, Pillai, Sureshkumar M. A., Santhamma, Bindu, Konda, Swapna, Pitta Venkata, Prabhakar, Blankenship, Logan, Liu, Junhao, Liu, Zexuan, Altwegg, Kristin A., Ebrahimi, Behnam, Pratap, Uday P., Li, Xiaonan, Valente, Philip T., Kost, Edward, Sareddy, Gangadhara R., Vadlamudi, Ratna K., Nair, Hareesh B., Tekmal, Rajeshwar R., Viswanadhapalli, Suryavathi
Publicado 2021

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer

por Li, Mengxing, Viswanadhapalli, Suryavathi, Santhamma, Bindu, Pratap, Uday P., Luo, Yiliao, Liu, Junhao, Altwegg, Kristin A., Tang, Weiwei, Liu, Zexuan, Li, Xiaonan, Ebrahimi, Behnam, Yan, Hui, Zou, Yi, Konda, Swapna, Sareddy, Gangadhara R., Xu, Zhenming, Chen, Yidong, Rao, Manjeet K., Brenner, Andrew J., Kaklamani, Virginia G., Tekmal, Rajeshwar R., Ahmed, Gulzar, Raj, Ganesh V., Nickisch, Klaus J., Nair, Hareesh B., Vadlamudi, Ratna K.
Publicado 2021